BTZ is a synthetic anticancer drug that inhibits NF-κB by binding to the 26S proteasome of cancer cells with high affinity and specificity, thereby resulting in reduced protein degradation tagging and apoptosis [16,17,18,19]. This evidence concerns the gene CASC3 and cancer.